FDA ex­perts turn thumbs down on PTC’s wob­bly case for its Duchenne MD drug

Af­ter a blis­ter­ing de­nun­ci­a­tion from the FDA of the da­ta that PTC Ther­a­peu­tics $PTCT has sub­mit­ted on be­half of its Duchenne mus­cu­lar dy­s­tro­phy drug ataluren, a pan­el of ex­perts vot­ed over­whelm­ing­ly against the drug, con­clud­ing that it’s still too ear­ly to say de­fin­i­tive­ly whether the drug works or not and ask­ing for some hard da­ta from a new study to lay the ques­tion to rest once and for all.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER